Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Journal of Experimental & Clinical Cancer Research

Figure 3

From: Inhibition of ADAM-17 more effectively down-regulates the Notch pathway than that of γ-secretase in renal carcinoma

Figure 3

Inhibition of either ADAM-17 or γ-secretase reduces proliferation of renal carcinoma cell lines. AB: 786-O (A) and OS-RC-2 (B) were treated with either Marimastat or DAPT at different doses then proliferation was measured by CCK-8 assay, the control group is no treatment. The mean cell activity (OD) of three experiments is presented (P<0.05). C: Expression of 786-O cells in the transwell assay by different doses of two types of inhibitor treatment cells.

Back to article page